➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKesson
Harvard Business School
Baxter
Mallinckrodt
Medtronic
Merck

Last Updated: July 6, 2020

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 022048


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

NDA 022048 describes TRIESENCE, which is a drug marketed by Novartis and is included in one NDA. It is available from one supplier. There are three patents protecting this drug. Additional details are available on the TRIESENCE profile page.

The generic ingredient in TRIESENCE is triamcinolone acetonide. There are fifty-one drug master file entries for this compound. Sixty-nine suppliers are listed for this compound. Additional details are available on the triamcinolone acetonide profile page.
Summary for 022048
Tradename:TRIESENCE
Applicant:Novartis
Ingredient:triamcinolone acetonide
Patents:3
Formulation / Manufacturing:see details
Pharmacology for NDA: 022048
Medical Subject Heading (MeSH) Categories for 022048
Suppliers and Packaging for NDA: 022048
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
TRIESENCE triamcinolone acetonide INJECTABLE;INTRAVITREAL 022048 NDA Alcon Laboratories, Inc. 0065-0543 0065-0543-01 1 BLISTER PACK in 1 CARTON (0065-0543-01) > 1 VIAL, GLASS in 1 BLISTER PACK > 1 mL in 1 VIAL, GLASS

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INTRAVITREALStrength40MG/ML (40MG/ML)
Approval Date:Nov 29, 2007TE:RLD:Yes
Patent:  Start TrialPatent Expiration:Jan 13, 2020Product Flag?YSubstance Flag?Delist Request?
Patented Use:USE FOR DELINEATION (VISUALIZATION) DURING A VITRECTOMY SURGICAL PROCEDURE
Patent:  Start TrialPatent Expiration:Dec 17, 2029Product Flag?YSubstance Flag?Delist Request?
Patent:  Start TrialPatent Expiration:Mar 10, 2029Product Flag?Substance Flag?Delist Request?
Patented Use:TREATMENT OF OPHTHALMIC DISORDERS

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Mallinckrodt
Harvard Business School
Express Scripts
Colorcon
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.